Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2016
Pan Canadian Rash Trial: A Randomized Phase III Trial Evaluating the Impact of a Prophylactic Skin Treatment Regimen on Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Induced Skin Toxicities in Patients With Metastatic Lung Cancer.
2 registry-linked trialsAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
In one paragraph
Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 53 papers.
0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
5.3field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized Controlled Trial of Systemic and Topical Treatments for Rash Secondary to Erlotinib in Advanced Stage IIIB or IV Non-Small Cell Lung Cancer
Prophylactic TCM for Mitigation of EGFR-TKI Related Dermatological Adverse Effect
Who cites it
53 citing papers in PubMed, 91 citations in OpenAlex.
- Results of the non-small cell lung cancer part of a phase III, open-label, randomized trial evaluating topical corticosteroid therapy for facial acneiform dermatitis induced by EGFR inhibitors: stepwise rank down from potent corticosteroid (FAEISS study, NCCH-1512).Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021Trial
- Minocycline Reduces Chemoradiation-Related Symptom Burden in Patients with Non-Small Cell Lung Cancer: A Phase 2 Randomized Trial.International journal of radiation oncology, biology, physics · 2020Trial
- A Randomized Controlled Trial of Epidermal Growth Factor Ointment for Treating Epidermal Growth Factor Receptor Inhibitor-Induced Skin Toxicities.The oncologist · 2020Trial
- Minocycline for symptom reduction during radiation therapy for head and neck cancer: a randomized clinical trial.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020Trial
- A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer.Annals of oncology : official journal of the European Society for Medical Oncology · 2016Trial
- Topical Zhiyang Pingfu Liquid for Moderate to Severe Skin Rash Associated With EGFRIs: A double-blinded randomized controlled trial.Integrative cancer therapiesTrial
- Efficacy of Prophylactic Traditional Chinese Medicine on Skin Toxicity of Afatinib inIntegrative cancer therapiesTrial
- Impact of prophylactic skin toxicity management on treatment continuity and clinical outcomes in EGFR-mutant non-small cell lung cancer treated with osimertinib: a 7-year real-world retrospective cohort study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Enabling precision therapy through dermatologic prophylaxis: lessons from COCOON.Journal of thoracic disease · 2026Article
- Preventive and Therapeutic Interventions for Anticancer Drug-induced Dermatologic Toxicities: a Scoping Review.Current oncology reports · 2026Article
- Exosome-Based Therapy for Skin Complications in Oncology Patients Treated with EGFR Inhibitors: A Case Report Highlighting the Need for Coordinated Dermato-Oncologic Care.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Mitigation and management of adverse events associated with amivantamab therapy.The oncologist · 2025Review
- Management of human epidermal growth factor receptor inhibitors-related acneiform rash: A position paper based on the first Europe/USA Delphi consensus process.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Article
- CYpHER: Catalytic extracellular targeted protein degradation with high potency and durable effect.bioRxiv : the preprint server for biology · 2024Article
- Evaluation of the additional prophylactic effect of topical steroid ointment to systemic minocycline against anti-epidermal growth factor antibody-induced skin toxicities in metastatic colorectal cancer treatment.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023Article
- Risk factor analysis for anti-epidermal growth factor receptor monoclonal antibody-induced skin toxicities in real-world metastatic colorectal cancer treatment.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023Article
- Impact of minocycline on outcomes of EGFR-mutant non-small cell lung cancer patients treated with EGFR-TKIs.Scientific reports · 2023Article
- Article
- The Effect of Topical Vitamin K1 on the Treatment of Cetuximab-Induced Skin Rashes in Metastatic Colorectal Cancer Patients.Advanced biomedical research · 2023Article
- A Drug Screening Reveals Minocycline Hydrochloride as a Therapeutic Option to Prevent Breast Cancer Cells Extravasation across the Blood-Brain Barrier.Biomedicines · 2022Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
14 authors at 1 institution in 1 country.
Barbara MeloskyBarbara Melosky, Vincent Ho, Cheryl Ho, Nevin Murray, Sophie Sun, and Janessa J. Laskin, British Columbia Cancer Agency (BCCA) Vancouver Centre, Vancouver; Helen Anderson, BCCA Vancouver Island Centre, Victoria; Wendy Lam, Burnaby Regional Hospital, Burnaby; Christopher W. Lee, BCCA Fraser Valley Cancer Centre, Surrey; Robert Winston, BCCA Abbotsford Centre, Abbotsford, British Columbia; Ronald L. Burkes, Mount Sinai Hospital; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, Ontario; Quincy Chu, Cross Cancer Institute, Edmonton; and Desiree Hao, Tom Baker Care Centre, Calgary, Alberta, Canada. bmelosky@bccancer.bc.ca.
Helen AndersonBarbara Melosky, Vincent Ho, Cheryl Ho, Nevin Murray, Sophie Sun, and Janessa J. Laskin, British Columbia Cancer Agency (BCCA) Vancouver Centre, Vancouver; Helen Anderson, BCCA Vancouver Island Centre, Victoria; Wendy Lam, Burnaby Regional Hospital, Burnaby; Christopher W. Lee, BCCA Fraser Valley Cancer Centre, Surrey; Robert Winston, BCCA Abbotsford Centre, Abbotsford, British Columbia; Ronald L. Burkes, Mount Sinai Hospital; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, Ontario; Quincy Chu, Cross Cancer Institute, Edmonton; and Desiree Hao, Tom Baker Care Centre, Calgary, Alberta, Canada.
Ronald L BurkesBarbara Melosky, Vincent Ho, Cheryl Ho, Nevin Murray, Sophie Sun, and Janessa J. Laskin, British Columbia Cancer Agency (BCCA) Vancouver Centre, Vancouver; Helen Anderson, BCCA Vancouver Island Centre, Victoria; Wendy Lam, Burnaby Regional Hospital, Burnaby; Christopher W. Lee, BCCA Fraser Valley Cancer Centre, Surrey; Robert Winston, BCCA Abbotsford Centre, Abbotsford, British Columbia; Ronald L. Burkes, Mount Sinai Hospital; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, Ontario; Quincy Chu, Cross Cancer Institute, Edmonton; and Desiree Hao, Tom Baker Care Centre, Calgary, Alberta, Canada.
Quincy ChuBarbara Melosky, Vincent Ho, Cheryl Ho, Nevin Murray, Sophie Sun, and Janessa J. Laskin, British Columbia Cancer Agency (BCCA) Vancouver Centre, Vancouver; Helen Anderson, BCCA Vancouver Island Centre, Victoria; Wendy Lam, Burnaby Regional Hospital, Burnaby; Christopher W. Lee, BCCA Fraser Valley Cancer Centre, Surrey; Robert Winston, BCCA Abbotsford Centre, Abbotsford, British Columbia; Ronald L. Burkes, Mount Sinai Hospital; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, Ontario; Quincy Chu, Cross Cancer Institute, Edmonton; and Desiree Hao, Tom Baker Care Centre, Calgary, Alberta, Canada.
Desiree HaoBarbara Melosky, Vincent Ho, Cheryl Ho, Nevin Murray, Sophie Sun, and Janessa J. Laskin, British Columbia Cancer Agency (BCCA) Vancouver Centre, Vancouver; Helen Anderson, BCCA Vancouver Island Centre, Victoria; Wendy Lam, Burnaby Regional Hospital, Burnaby; Christopher W. Lee, BCCA Fraser Valley Cancer Centre, Surrey; Robert Winston, BCCA Abbotsford Centre, Abbotsford, British Columbia; Ronald L. Burkes, Mount Sinai Hospital; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, Ontario; Quincy Chu, Cross Cancer Institute, Edmonton; and Desiree Hao, Tom Baker Care Centre, Calgary, Alberta, Canada.
Vincent HoBarbara Melosky, Vincent Ho, Cheryl Ho, Nevin Murray, Sophie Sun, and Janessa J. Laskin, British Columbia Cancer Agency (BCCA) Vancouver Centre, Vancouver; Helen Anderson, BCCA Vancouver Island Centre, Victoria; Wendy Lam, Burnaby Regional Hospital, Burnaby; Christopher W. Lee, BCCA Fraser Valley Cancer Centre, Surrey; Robert Winston, BCCA Abbotsford Centre, Abbotsford, British Columbia; Ronald L. Burkes, Mount Sinai Hospital; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, Ontario; Quincy Chu, Cross Cancer Institute, Edmonton; and Desiree Hao, Tom Baker Care Centre, Calgary, Alberta, Canada.
Cheryl HoBarbara Melosky, Vincent Ho, Cheryl Ho, Nevin Murray, Sophie Sun, and Janessa J. Laskin, British Columbia Cancer Agency (BCCA) Vancouver Centre, Vancouver; Helen Anderson, BCCA Vancouver Island Centre, Victoria; Wendy Lam, Burnaby Regional Hospital, Burnaby; Christopher W. Lee, BCCA Fraser Valley Cancer Centre, Surrey; Robert Winston, BCCA Abbotsford Centre, Abbotsford, British Columbia; Ronald L. Burkes, Mount Sinai Hospital; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, Ontario; Quincy Chu, Cross Cancer Institute, Edmonton; and Desiree Hao, Tom Baker Care Centre, Calgary, Alberta, Canada.
Wendy LamBarbara Melosky, Vincent Ho, Cheryl Ho, Nevin Murray, Sophie Sun, and Janessa J. Laskin, British Columbia Cancer Agency (BCCA) Vancouver Centre, Vancouver; Helen Anderson, BCCA Vancouver Island Centre, Victoria; Wendy Lam, Burnaby Regional Hospital, Burnaby; Christopher W. Lee, BCCA Fraser Valley Cancer Centre, Surrey; Robert Winston, BCCA Abbotsford Centre, Abbotsford, British Columbia; Ronald L. Burkes, Mount Sinai Hospital; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, Ontario; Quincy Chu, Cross Cancer Institute, Edmonton; and Desiree Hao, Tom Baker Care Centre, Calgary, Alberta, Canada.
Christopher W LeeBarbara Melosky, Vincent Ho, Cheryl Ho, Nevin Murray, Sophie Sun, and Janessa J. Laskin, British Columbia Cancer Agency (BCCA) Vancouver Centre, Vancouver; Helen Anderson, BCCA Vancouver Island Centre, Victoria; Wendy Lam, Burnaby Regional Hospital, Burnaby; Christopher W. Lee, BCCA Fraser Valley Cancer Centre, Surrey; Robert Winston, BCCA Abbotsford Centre, Abbotsford, British Columbia; Ronald L. Burkes, Mount Sinai Hospital; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, Ontario; Quincy Chu, Cross Cancer Institute, Edmonton; and Desiree Hao, Tom Baker Care Centre, Calgary, Alberta, Canada.
Natasha B LeighlBarbara Melosky, Vincent Ho, Cheryl Ho, Nevin Murray, Sophie Sun, and Janessa J. Laskin, British Columbia Cancer Agency (BCCA) Vancouver Centre, Vancouver; Helen Anderson, BCCA Vancouver Island Centre, Victoria; Wendy Lam, Burnaby Regional Hospital, Burnaby; Christopher W. Lee, BCCA Fraser Valley Cancer Centre, Surrey; Robert Winston, BCCA Abbotsford Centre, Abbotsford, British Columbia; Ronald L. Burkes, Mount Sinai Hospital; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, Ontario; Quincy Chu, Cross Cancer Institute, Edmonton; and Desiree Hao, Tom Baker Care Centre, Calgary, Alberta, Canada.
Nevin MurrayBarbara Melosky, Vincent Ho, Cheryl Ho, Nevin Murray, Sophie Sun, and Janessa J. Laskin, British Columbia Cancer Agency (BCCA) Vancouver Centre, Vancouver; Helen Anderson, BCCA Vancouver Island Centre, Victoria; Wendy Lam, Burnaby Regional Hospital, Burnaby; Christopher W. Lee, BCCA Fraser Valley Cancer Centre, Surrey; Robert Winston, BCCA Abbotsford Centre, Abbotsford, British Columbia; Ronald L. Burkes, Mount Sinai Hospital; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, Ontario; Quincy Chu, Cross Cancer Institute, Edmonton; and Desiree Hao, Tom Baker Care Centre, Calgary, Alberta, Canada.
Sophie SunBarbara Melosky, Vincent Ho, Cheryl Ho, Nevin Murray, Sophie Sun, and Janessa J. Laskin, British Columbia Cancer Agency (BCCA) Vancouver Centre, Vancouver; Helen Anderson, BCCA Vancouver Island Centre, Victoria; Wendy Lam, Burnaby Regional Hospital, Burnaby; Christopher W. Lee, BCCA Fraser Valley Cancer Centre, Surrey; Robert Winston, BCCA Abbotsford Centre, Abbotsford, British Columbia; Ronald L. Burkes, Mount Sinai Hospital; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, Ontario; Quincy Chu, Cross Cancer Institute, Edmonton; and Desiree Hao, Tom Baker Care Centre, Calgary, Alberta, Canada.
Robert WinstonBarbara Melosky, Vincent Ho, Cheryl Ho, Nevin Murray, Sophie Sun, and Janessa J. Laskin, British Columbia Cancer Agency (BCCA) Vancouver Centre, Vancouver; Helen Anderson, BCCA Vancouver Island Centre, Victoria; Wendy Lam, Burnaby Regional Hospital, Burnaby; Christopher W. Lee, BCCA Fraser Valley Cancer Centre, Surrey; Robert Winston, BCCA Abbotsford Centre, Abbotsford, British Columbia; Ronald L. Burkes, Mount Sinai Hospital; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, Ontario; Quincy Chu, Cross Cancer Institute, Edmonton; and Desiree Hao, Tom Baker Care Centre, Calgary, Alberta, Canada.
Janessa J LaskinBarbara Melosky, Vincent Ho, Cheryl Ho, Nevin Murray, Sophie Sun, and Janessa J. Laskin, British Columbia Cancer Agency (BCCA) Vancouver Centre, Vancouver; Helen Anderson, BCCA Vancouver Island Centre, Victoria; Wendy Lam, Burnaby Regional Hospital, Burnaby; Christopher W. Lee, BCCA Fraser Valley Cancer Centre, Surrey; Robert Winston, BCCA Abbotsford Centre, Abbotsford, British Columbia; Ronald L. Burkes, Mount Sinai Hospital; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, Ontario; Quincy Chu, Cross Cancer Institute, Edmonton; and Desiree Hao, Tom Baker Care Centre, Calgary, Alberta, Canada.
BC Cancer Agency · CA
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeErlotinib is an epidermal growth factor receptor inhibitor approved for patients with advanced non-small-cell lung cancer (NSCLC) whose epidermal growth factor receptor expression status is positive or unknown. Although it is efficacious, erlotinib can cause skin toxicity. This prospective, randomized phase III trial examined the effect of prophylactic treatment of erlotinib-induced skin rash. PATIENTS AND
methodsPatients receiving erlotinib in the second- or third-line setting for advanced NSCLC were randomly assigned to prophylactic minocycline (100 mg twice per day for 4 weeks), reactive treatment (after rash developed, per grade of rash), or no treatment unless severe (grade 3). Rash incidence and severity, time to maximal rash, time to resolution, and overall survival (OS) were compared among treatment groups.
resultsIn all, 150 patients were randomly assigned, 50 to each of three treatment arms. The incidence of skin toxicity was 84% regardless of treatment arm. Prophylactic treatment with minocycline significantly lengthened the time to the most severe grade of rash. Grade 3 rash was significantly higher in the no-treatment arm. OS was not significantly different among treatment arms, but patients receiving prophylactic or reactive treatments had a longer OS (7.6 and 8 months, respectively) than those who received no rash treatment (6 months). Rash was not self-limiting.
conclusionThe incidence of all grades of rash did not differ statistically among the three arms, so the trial was negative. The incidence of grade 3 skin toxicities was reduced in patients who were treated with prophylactic minocycline or reactive treatment. Efficacy was not compromised. Prophylactic minocycline and reactive treatment are both acceptable options for the necessary treatment of erlotinib-induced rash in the second- or third-line setting of metastatic NSCLC.
Indexed as
Carcinoma, Non-Small-Cell LungErlotinib HydrochlorideExanthemaFemaleHumansLung NeoplasmsMaleMiddle AgedMinocyclineProspective StudiesProtein Kinase InhibitorsErlotinib HydrochlorideMinocyclineProtein Kinase Inhibitors
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT00473083ClinicalTrials.gov
NCT05204758ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.